JP2018507166A5 - - Google Patents

Download PDF

Info

Publication number
JP2018507166A5
JP2018507166A5 JP2017528877A JP2017528877A JP2018507166A5 JP 2018507166 A5 JP2018507166 A5 JP 2018507166A5 JP 2017528877 A JP2017528877 A JP 2017528877A JP 2017528877 A JP2017528877 A JP 2017528877A JP 2018507166 A5 JP2018507166 A5 JP 2018507166A5
Authority
JP
Japan
Prior art keywords
antibody
antibiotic
conjugate compound
alkyl
following formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017528877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507166A (ja
JP6751393B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/063515 external-priority patent/WO2016090040A1/en
Publication of JP2018507166A publication Critical patent/JP2018507166A/ja
Publication of JP2018507166A5 publication Critical patent/JP2018507166A5/ja
Application granted granted Critical
Publication of JP6751393B2 publication Critical patent/JP6751393B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017528877A 2014-12-03 2015-12-02 抗staphylococcus aureus抗体リファマイシン抱合体及びその使用 Expired - Fee Related JP6751393B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462087213P 2014-12-03 2014-12-03
US62/087,213 2014-12-03
PCT/US2015/063515 WO2016090040A1 (en) 2014-12-03 2015-12-02 Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof

Publications (3)

Publication Number Publication Date
JP2018507166A JP2018507166A (ja) 2018-03-15
JP2018507166A5 true JP2018507166A5 (enExample) 2019-01-17
JP6751393B2 JP6751393B2 (ja) 2020-09-02

Family

ID=55022690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017528877A Expired - Fee Related JP6751393B2 (ja) 2014-12-03 2015-12-02 抗staphylococcus aureus抗体リファマイシン抱合体及びその使用

Country Status (11)

Country Link
US (1) US20180125995A1 (enExample)
EP (1) EP3226908A1 (enExample)
JP (1) JP6751393B2 (enExample)
KR (1) KR20170086542A (enExample)
CN (1) CN107249642A (enExample)
BR (1) BR112017011478A2 (enExample)
CA (1) CA2966211A1 (enExample)
HK (1) HK1244230A1 (enExample)
MX (1) MX2017007231A (enExample)
RU (1) RU2017118792A (enExample)
WO (1) WO2016090040A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10533058B2 (en) 2013-12-16 2020-01-14 Genentech Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
AU2014364927A1 (en) 2013-12-16 2016-07-07 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CN108064246A (zh) 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
SG11201804268RA (en) 2015-12-04 2018-06-28 Seattle Genetics Inc Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017152083A1 (en) * 2016-03-04 2017-09-08 Genentech, Inc. Process for the preparation of an antibody-rifamycin conjugate
AU2017359043B2 (en) 2016-11-08 2022-06-16 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
EA202091672A1 (ru) 2018-01-08 2021-02-01 Регенерон Фармасьютикалз, Инк. Стероиды и их антитело-конъюгаты
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
CN111939256B (zh) * 2020-07-06 2022-05-31 中国药科大学 一种具有细菌调理特性的抗菌辅助材料及其制备方法和应用
WO2023023378A1 (en) * 2021-08-20 2023-02-23 Rutgers, The State University Of New Jersey DUAL-TARGETED RNA POLYMERASE INHIBITORS: CONJUGATES OF BENZOXAZINO- AND SPIRO-RIFAMYCINS WITH Nα-AROYL- N-ARYL-PHENYLALANINAMIDES
US20250319024A1 (en) * 2021-08-27 2025-10-16 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to infectious disease

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB877732A (en) 1958-08-12 1961-09-20 Lepetit Spa The antibiotic rifomycin, its components and methods of preparing same
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4610919A (en) 1985-06-14 1986-09-09 Fiber Bond Corporation Binder for fibrous padding
JP2544375B2 (ja) 1986-07-14 1996-10-16 鐘淵化学工業株式会社 アルキル置換ベンゾキサジノリフアマイシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1304363C (en) 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US6660267B1 (en) 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
US5545721A (en) 1992-12-21 1996-08-13 Ophidian Pharmaceuticals, Inc. Conjugates for the prevention and treatment of sepsis
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5981522A (en) 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
JP3963976B2 (ja) 1995-12-08 2007-08-22 株式会社カネカ クラミジア感染症治療剤
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
US7101692B2 (en) * 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
JP2003503015A (ja) * 1999-05-03 2003-01-28 メダレツクス・インコーポレーテツド スタフィロコッカス・アウレウスに対するヒト抗体
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7017718B2 (en) * 2001-06-28 2006-03-28 Freni Brembo S.P.A Composite disc for a disc brake having a splittable braking band
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
WO2003043583A2 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US7122525B2 (en) * 2001-11-21 2006-10-17 Activbiotics, Inc. Targeted therapeutics and uses thereof
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
CN1930288B (zh) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
ES2362419T3 (es) 2002-04-09 2011-07-05 Kyowa Hakko Kirin Co., Ltd. Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CA2494104A1 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2006504971A (ja) 2002-11-01 2006-02-09 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド,ア・ボディー・コーポレイト マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
CN1894259A (zh) 2003-08-22 2007-01-10 活跃生物工艺学公司 利福霉素类似物及其应用
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
NZ583292A (en) * 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CN1918172B (zh) 2003-12-23 2011-09-14 活跃生物工艺学公司 利福霉素类似物及其用途
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
AU2006269422B2 (en) 2005-07-07 2012-12-06 Seagen Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
EA016059B1 (ru) * 2005-08-11 2012-01-30 Тарганта Терапьютикс Инк. Фосфонированные рифамицины и их применение для профилактики и лечения костных и суставных инфекций
BRPI0620158A2 (pt) 2005-12-14 2012-04-24 Activbiotics Pharma Llc análogos de rifamicina e seus usos
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
MY188455A (en) 2007-10-19 2021-12-09 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
AU2009246510B2 (en) 2008-05-12 2014-02-13 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
EP2324041A4 (en) 2008-08-13 2012-06-13 Targanta Therapeutics Corp PHOSPHONIZED RIFAMYCINS AND ITS APPLICATION FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
KR101906177B1 (ko) * 2008-12-10 2018-10-10 시플라 리미티드 리팍시민 복합체
CA2768204A1 (en) * 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Gram-positive bacteria specific binding compounds
EP2678037B1 (en) 2011-02-25 2014-12-03 Lonza Ltd Branched linker for protein drug conjugates
EP2922818B1 (en) * 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
MX369022B (es) 2013-05-31 2019-10-25 Genentech Inc Anticuerpos anti-ácido teicoico de la pared celular y conjugados.
US9884126B2 (en) * 2013-05-31 2018-02-06 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
US10533058B2 (en) * 2013-12-16 2020-01-14 Genentech Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
AU2014364927A1 (en) * 2013-12-16 2016-07-07 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof

Similar Documents

Publication Publication Date Title
JP2018507166A5 (enExample)
JP2018503603A5 (enExample)
RU2017118793A (ru) Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
RU2017118792A (ru) Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
TWI864472B (zh) 抗體的特異性偶聯
JP2016525343A5 (enExample)
ZA202107015B (en) Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
JP2016502504A5 (enExample)
JP2018516243A5 (enExample)
JP2015527318A5 (enExample)
JP2015534580A5 (enExample)
JP2014502266A5 (enExample)
MX2021014960A (es) Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo.
JP2015534578A5 (enExample)
JP2017537893A5 (enExample)
RU2015151046A (ru) Антитела против стеночной тейхоевой кислоты и их конъюгаты
JP2017527532A5 (enExample)
JP2018511628A5 (enExample)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
CN108026123A (zh) 用于偶联的亲水链接体
EA201270738A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
HRP20181646T2 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
JP2013512903A5 (enExample)
EA201890236A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение